(Albany, New York)- 3rd Sep 2026, The market dynamics for Spinal Cord Injury (SCI) are witnessing steady growth driven by the growing diagnosed patient pool, increasing awareness of traumatic and non-traumatic spinal cord injuries, advances in diagnostic and patient stratification pathways, and the significant unmet need for therapies that can promote neurological recovery and functional restoration. Additionally, the development of promising neuroprotective, anti-inflammatory, regenerative, and neuromodulatory therapies such as STEMIRAC, Oremepermin alfa (KP-100IT), Elezanumab (ABT-555), Neuro-Cells, and Unasnemab (MT-3921) is expected to further propel the Spinal Cord Injury market during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Spinal Cord Injury (SCI) Market Insights, Epidemiology and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Spinal Cord Injury, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Spinal Cord Injury Market
The market size for Spinal Cord Injury in the leading markets is expected to grow significantly by 2036.
The 7MM Spinal Cord Injury market was valued at approximately USD 350 million in 2025 and is projected to expand at a 18.3% CAGR during 2026–2036.
According to DelveInsight’s estimates, there were approximately 1 million diagnosed prevalent cases of Spinal Cord Injury across the 7MM in 2025, with the number expected to rise by 2036.
In 2025, the United States accounted for approximately 300,000 diagnosed prevalent cases of SCI, with the number expected to increase by 2036.
According to DelveInsight’s estimates, there were approximately 19,000 acute (incidence) cases of SCI across the United States in 2025, with the number expected to rise by 2036.
In 2025, the United States reported approximately 250,000 male and 60,000 female cases of SCI, with both numbers expected to increase by 2036.
In 2025, EU4 and the UK accounted for approximately 500,000 diagnosed prevalent cases of SCI, including approximately 380,000 traumatic and 150,000 non-traumatic cases.
In 2025, Japan accounted for approximately USD 50 million of the total SCI market and recorded approximately 60,000 cases due to falls, followed by approximately 20,000 cases due to vehicular accidents.
In 2025, the United States accounted for approximately 44% of the total SCI market, with a market size of approximately USD 150 million.
STEMIRAC, developed by Nipro Corporation, is the only conditionally approved SCI-specific therapy globally and received conditional approval from Japan’s PMDA for neurological symptoms associated with SCI.
Pregabalin (LYRICA) is the sole FDA-approved medication for SCI-related neuropathic pain, while current treatment largely emphasizes rehabilitation and symptom management.
Leading Spinal Cord Injury companies, including AbbVie, Mitsubishi Tanabe Pharma America, Neuroplast, Kringle Pharma, Pharmazz, and others, are actively developing innovative therapies expected to transform the SCI treatment landscape over the coming years.
Promising Spinal Cord Injury therapies in clinical development include Oremepermin alfa (KP-100IT), Elezanumab (ABT-555), Neuro-Cells, and Unasnemab (MT-3921).
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/spinal-cord-injury-market
Key Factors Driving the Spinal Cord Injury Market
Growing Diagnosed Patient Pool
The increasing diagnosed prevalence of Spinal Cord Injury across the 7MM is expected to support market growth. Approximately 1 million diagnosed prevalent cases were estimated across the 7MM in 2025, with the patient pool expected to increase through 2036.
Rising Awareness and Improved Diagnosis
Advances in diagnostic and patient stratification pathways, together with increasing awareness of both traumatic and non-traumatic SCI subtypes, are enabling earlier identification and more timely clinical intervention, particularly in acute injury settings.
Expansion of Neuroprotective and Regenerative Therapies
The SCI pipeline is increasingly focused on therapies designed to move beyond symptom management toward neuroprotection, axonal regeneration, cell replacement, and functional recovery. Oremepermin alfa, Elezanumab, Neuro-Cells, and Unasnemab represent mechanistically diverse approaches in clinical development.
Significant Unmet Need for Disease-Modifying Treatments
Current SCI management primarily emphasizes immediate medical intervention, surgery, pharmacological symptom management, and rehabilitation. The absence of broadly available curative or disease-modifying treatments creates a significant unmet need for therapies capable of promoting nerve regeneration and functional recovery.
Spinal Cord Injury Competitive Landscape
The Spinal Cord Injury treatment landscape is steadily evolving, with current management focused on acute medical intervention, surgical procedures, pharmacological therapies, pain management, and rehabilitation. Pregabalin (LYRICA) is the sole FDA-approved medication for SCI-related neuropathic pain, while methylprednisolone has historically been used in acute injury management but its routine use has become increasingly contested because of tolerability concerns.
STEMIRAC, developed by Nipro Corporation, is an autologous mesenchymal stem cell therapy designed to treat patients with traumatic SCI. It involves isolating mesenchymal stem cells from the patient’s bone marrow, culturing them in vitro, and cryopreserving them for future use. The therapy received conditional approval from Japan’s PMDA in 2018 for neurological symptoms associated with SCI.
The emerging pipeline is focused on moving SCI treatment beyond symptom control toward neuroprotection and functional recovery. Oremepermin alfa (KP-100IT), developed by Kringle Pharma, is an intrathecal formulation of hepatocyte growth factor designed to protect nerve cells and facilitate axonal regeneration. A Phase III clinical trial has been completed in Japan, with an additional study planned, while preparations are underway for a US IND filing.
Elezanumab (ABT-555), developed by AbbVie, is an investigational RGMA protein inhibitor administered by IV infusion and is anticipated to enter the US market in 2028. Neuro-Cells, developed by Neuroplast, is a human neural stem cell-based therapy intended to support neuroprotection through the release of neurotrophic factors. Unasnemab (MT-3921) from Mitsubishi Tanabe Pharma America is another emerging RGMA-targeting therapy being investigated for acute traumatic cervical SCI.
These emerging therapies are expected to further reshape the Spinal Cord Injury treatment landscape over the forecast period.
Discover more about therapies set to grab major Spinal Cord Injury market share @ Spinal Cord Injury Treatment Landscape
Recent Developments in the Spinal Cord Injury Market
In December 2025, Kringle Pharma submitted an application to the European Medicines Agency seeking orphan drug designation for oremepermin alfa in acute spinal cord injury. The therapy had already received orphan drug designation for acute SCI in Japan in September 2019 and the United States in June 2025.
In February 2024, Kringle Pharma reported topline results from its Phase III study evaluating oremepermin alfa for the treatment of acute spinal cord injury.
In July 2023, Nipro Corporation initiated a corporate clinical trial for chronic SCI, expanding the potential indication of STEMIRAC beyond subacute SCI.
In February 2016, STEMIRAC was designated as a breakthrough product under Japan’s SAKIGAKE designation system, which aims to accelerate the development of regenerative medical products for neurological symptoms and functional disorders associated with SCI.
What is Spinal Cord Injury?
Spinal Cord Injury (SCI) refers to a sudden disruption of the spinal cord’s neuronal tissue within the spinal canal resulting from trauma, disease, or degeneration. Depending on the level and type of damage, SCI can cause varying degrees of motor, sensory, and autonomic dysfunction, which may be temporary or permanent.
SCI may be classified as traumatic or non-traumatic. Traumatic SCI can result from events such as vehicular accidents and falls, while non-traumatic SCI may arise from diseases, degeneration, tumors, infections, or other conditions affecting the spinal cord.
Effective SCI management requires a comprehensive clinical examination and neurological classification, supported by detailed radiological assessments of the vertebral column. Treatment involves a multidisciplinary approach encompassing immediate medical intervention, surgical procedures, pharmacological therapies, and rehabilitation programs.
The condition can trigger secondary injury processes involving inflammation, ischemia, and neuronal cell death, extending damage beyond the initial injury site. The absence of a curative treatment, high lifetime care costs, and the profound impact on patients and caregivers contribute to the significant unmet medical need in SCI.
Spinal Cord Injury Epidemiology Segmentation
The Spinal Cord Injury epidemiology section provides insights into the historical and current SCI patient pool and forecasted trends across the seven major markets. The Spinal Cord Injury market report provides epidemiological analysis for the study period 2022–2036, segmented into:
Acute (Incident) Cases of SCI
Total Diagnosed Prevalent Cases of SCI
Gender-specific Diagnosed Prevalent Cases of SCI
Etiology-specific Diagnosed Prevalent Cases of SCI
Etiology-specific Diagnosed Prevalent Cases of Traumatic SCI
Scope of the Spinal Cord Injury Market Report
Therapeutic Assessment: Current marketed and emerging therapies for Spinal Cord Injury
Spinal Cord Injury Market Dynamics: Key market forecast assumptions, pricing trends, therapy uptake, patient burden, and market outlook
Key Companies: AbbVie, Mitsubishi Tanabe Pharma America, Neuroplast, Kringle Pharma, Pharmazz, and others
Key Therapies: STEMIRAC, Oremepermin alfa (KP-100IT), Elezanumab (ABT-555), Neuro-Cells, Unasnemab (MT-3921), and others
Competitive Intelligence Analysis: SWOT Analysis and Conjoint Analysis
Unmet Needs, KOL’s Views, Analyst’s Views, Spinal Cord Injury Market Access and Reimbursement
To know more about Spinal Cord Injury companies working in the treatment market, visit @ Spinal Cord Injury Clinical Trials and Therapeutic Assessment
Table of Contents
Spinal Cord Injury Market Report Introduction
Key Insights
Executive Summary
Key Events
Disease Background and Overview
Types of Spinal Cord Injury
Causes and Risk Factors
Signs and Symptoms
Pathophysiology
Biomarkers
Diagnosis
Treatment and Management
Epidemiology and Patient Population of Spinal Cord Injury
Country-Specific Patient Population of Spinal Cord Injury
Patient Journey
Spinal Cord Injury Marketed Drugs
Spinal Cord Injury Emerging Drugs
Spinal Cord Injury Market Outlook
Country-Wise Spinal Cord Injury Market Analysis (2022–2036)
Spinal Cord Injury Market Access and Reimbursement of Therapies
Spinal Cord Injury Market Drivers
Spinal Cord Injury Market Barriers
Spinal Cord Injury Appendix
Spinal Cord Injury Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
